Response to Neratinib and Xeloda Combo Seen in Breast Cancer Patients with Brain Metastasis

Response to Neratinib and Xeloda Combo Seen in Breast Cancer Patients with Brain Metastasis

Combining Puma Biotechnology’s candidate therapy PB272, also known as neratinib, with the chemotherapy drug Xeloda (capecitabine) appears to have therapeutic potential for patients with advanced HER2-positive breast cancer and brain metastasis, who were not previously treated with Tykerb (lapatinib), a clinical study reports.

Results from the ongoing, multicenter Phase 2 trial (NCT01494662) found this combo therapy effectively shank metastatic brain tumors in nearly half of treated patients, and did so with tolerable toxicity. These positive results support further research into the use of neratinib to treat breast cancer patients with brain metastases.

The findings were featured in an oral presentation, “TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM),” given at the recent 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation is also available on Puma’s website.

“As a small molecule that can cross the blood brain barrier, neratinib potentially offers patients with HER2-positive metastatic breast cancer that has metastasized to the CNS a novel HER2 targeted treatment option,” Alan Auerbach, CEO and president of Puma Biotechnology, said in a press release.

Lead by investigators at Dana-Farber Cancer Institute, in collaboration with the Translational Breast Cancer Research Consortium (TBCRC), the Phase 2 trial includes three cohorts of patients with breast cancer and brain metastasis larger than 1 cm.

In the first cohort, a total of 40 patients were given neratinib as a stand-alone therapy. Results were published in the Journal of Clinical Oncology, in the study “Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases.” They showed that neratinib alone failed to produce treatment response in at least four patients, the primary objective for this group, and did not demonstrate active therapeutic potential.

The second cohort consists of five patients with brain metastasis who are suitable candidates for surgery to remove the tumor. These patients are receiving neratinib monotherapy before and after surgical treatment. Results on this cohort will be presented at a future medical meeting.

To improve neratinib’s activity in the central nervous system (CNS), researchers are also testing its efficacy in combination with chemotherapy. In the third cohort, so far comprising 39 patients and expected to reach a total of 60, all patients received once-daily, oral neratinib, with additional twice-daily Xeloda, for 14 days followed by seven days off-treatment.

Results from this cohort, presented at the ASCO 2017 meeting, focused on those patients who had not received prior treatment with ‎Tykerb, a targeted chemical therapy. About 30 percent of patients had undergone surgery, 65 percent had received prior whole brain radiotherapy, and 35 percent had been given stereotactic radiosurgery to the brain. Stereotactic radiosurgery is a type of focused radiation beam therapy to lessen the impact on surrounding healthy tissue.

The combination of neratinib plus Xeloda was seen to promote a CNS objective response, using a combination of measurements, in about 49 percent of the patients. Under a secondary trial measure that reported response according to criteria known as RANO-BM (response assessment in neuro-oncology-brain metastasis), 24 percent showed a CNS objective response.

Patients had a median time to CNS progression of 5.5 months, and median overall survival was 13.5 months, but survival data are still immature, the researchers said.

The combo therapy was well-tolerated, with the most common treatment-related adverse event being treatable diarrhea.

“Neratinib given in combination with capecitabine showed promising activity in patients with heavily pre-treated HER2-positive disease metastatic to the CNS,” said Rachel Freedman, MD, with the Dana-Farber Cancer Institute.

“Despite the introduction of several new treatments for patients with HER2-positive metastatic breast cancer, CNS progression events remain a major source of patient morbidity and mortality. Based on the results from TBCRC-022 [the clinical trial], we look forward to additional trials with neratinib-based regimens for HER2-positive CNS disease,” Freedman added.

Related --

Related --

3 comments

  1. maureen martin says:

    am at a terrible cross roads…Since March 2016 major mets..first mets was in July 2013 breast met to lung…Faslodex for 1yr, Xeloda, combo, Ixempra, then Ibrance and Ibrance Faslodex…then in March 205,,mets to brain, rt eye, liver, al bones..cranium, ribs, spinal cord, etc., ,,then on Gemzar/Taxol from April 18th to Nov 5, 2016, Had Gamma Knife surgery for 4 lesions in brain also in April..then eye get better..no lesions…Oct 24…more brain lesion Drs. thought I had 6 when in for more Gamma Knife in late Oct ,7 hr. procedure 25 brain lesions….than in late Nov.. switched to Gemzar/Carboplatin….more liver increase switch in Jan to Halaven then approved for Opdivo in April…more liver smaller brain..took of Opdivo(as it takes 12 weeks to kick in…then on CMF…50% dosage chemo. NOW Brian has major swollen and bleeding not currently a candidate for whole brain…everyone is throwing in the towel??

    • SOG says:

      Hi , I am sorry about you having swollen and bleeding and not able to to WBRT, is this the only options given by doctor? I am having a difficult time deciding whether I should do WBTR or not for 20 lesions. I want try focal therapy first. I was initially scheduled for Gamma Knife for 4 lesions did a MRI right before that showed 20 lesions , so the Radiologist Onco told me I was not candidate to Gamma Knife any longer. Did I understand right that you had 7 hours procedure for 25 lesions? You did twice the SRST ? Can I ask where did you have done? I heard of others cases but could not convince my Radiologist. Hope you have got other treatment option. I can’t seem to get over the fear of whole brain radiation ..

  2. AditiGhosh says:

    Ya! I agree with you and it is really good post.As We Defeat Cancer Using Our Global Platform
    I Suggest Fight Cancer Global a best platform is designed to connect and unite Cancer hospitals, doctors, fighters and survivors together, to Inspire and Empower.

Leave a Comment

Your email address will not be published. Required fields are marked *